0.00Open0.00Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover735.38%IV-51.46%PremiumJan 17, 2025Expiry Date1.59Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8871Delta0.0459Gamma1.49Leverage Ratio-0.0333Theta0.0002Rho1.32Eff Leverage0.0011Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet